Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats

References

• MenterAGottliebAFeldmanSRGuidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsJ Am Acad Dermatol200858582685018423260
   PubMed Web of Science ®Google Scholar
• GottliebAKormanNJGordonKBGuidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologicsJ Am Acad Dermatol200858585186418423261
   PubMed Web of Science ®Google Scholar
• DeeksEDApremilast: a review in psoriasis and psoriatic arthritisDrugs201575121393140326220911
   PubMed Web of Science ®Google Scholar
• HoffmanMBHillDFeldmanSRCurrent challenges and emerging drug delivery strategies for the treatment of psoriasisExpert Opin Drug Deliv201613101461147327164301
   PubMed Web of Science ®Google Scholar
• Assessment report of Apremilast (Otezla)Committee for medicinal products for human useEuropean Medicines Agency2014
   Google Scholar
• FoodUSAdministrationDrugCentre for Drug Evaluation and ResearchPharmacolocgical Overview of OTEZLA (apremilast) tablets Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205437Orig1s000PharmR.pdfAccessed October 1, 2018
   Google Scholar
• PappKCatherJCRosophLEfficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trialLancet2012380984373874622748702
   PubMed Web of Science ®Google Scholar
• OTEZLA® (apremilast) tablets [Prescribing Information]2017Celgene Corporation SummitNew Jersay Available from https://media.celgene.com/content/uploads/otezla-pi.pdfAccessed October 1, 2018
   Google Scholar
• TangMHuPHuangSZhengQYuHHeYDevelopment of an extended-release formulation for apremilast and a level A in vitro- in vivo correlation study in beagle dogsChem Pharm Bull201664111607161527568485
   PubMedGoogle Scholar
• ZhangYWischkeCMittalSMitraASchwendemanSPDesign of controlled release PLGA microspheres for hydrophobic fenretinideMol Pharm20161382622263027144450
   PubMedGoogle Scholar
• CosséAKönigCLamprechtAWagnerKGHot melt extrusion for sustained protein release: matrix erosion and in vitro release of PLGA-based implantsAAPS PharmSciTech2017181152627193002
   PubMed Web of Science ®Google Scholar
• LiLLiCZhouJEffective sustained release of 5-FU-loaded PLGA implant for improving therapeutic index of 5-FU in colon tumorInt J Pharm20185501–238038730040972
   PubMedGoogle Scholar
• AnwerMKAl-MansoorMAJamilSAl-ShdefatRAnsariMNShakeelFDevelopment and evaluation of PLGA polymer based nanoparticles of quercetinInt J Biol Macromol20169221321927381585
   PubMed Web of Science ®Google Scholar
• AnwerMKJamilSAnsariMJIqbalMImamFShakeelFDevelopment and evaluation of olmesartan medoxomil loaded PLGA nanoparticlesMater Res Innov2016203193197
   Google Scholar
• PadhiSKapoorRVermaDPandaAKIqbalZFormulation and optimization of topotecan nanoparticles: in vitro characterization, cytotoxicity, cellular uptake and pharmacokinetic outcomesJ Photochem Photobiol B201818322223229729631
   PubMed Web of Science ®Google Scholar
• AnwerMKAl-ShdefatREzzeldinEAlshahraniSMAlshetailiASIqbalMPreparation, evaluation and bioavailability studies of eudragit coated PLGA nanoparticles for sustained release of eluxadoline for the treatment of irritable bowel syndromeFront Pharmacol2017884429209215
   PubMed Web of Science ®Google Scholar
• AbrahamJMishraVChaudhariKMittalVTopical compositions of apremilastPatent NoWO2017216738A12017
   Google Scholar
• GanarajanGSharmaDCTangriPKothiyalPDesign and characterization of apremilast loaded emulgel for topical treatmentIJPBS201883552562
   Google Scholar
• KushwahaASRepkaMANarasimha MurthySA Novel Apremilast Nail Lacquer Formulation for the Treatment of Nail PsoriasisAAPS PharmSciTech20171882949295628455829
   PubMedGoogle Scholar
• LonkarNADoleMNSawantSDDevelopment and validation of UV spectrophotometric method for the estimation of apremilast in bulk form by absorbance maxima methodWorld J Pharm Pharm Sci201767758766
   Google Scholar
• IqbalMEzzeldinEAl-RashoodKAAl-ShdefatRAnwerMKHigh throughput µ-SPE based elution coupled with UPLC-MS/MS for determination of eluxadoline in plasma sample: application in pharmacokinetic characterization of PLGA nanoparticle formulations in ratsJ Pharm Biomed Anal201814917217829121571
   PubMedGoogle Scholar
• JainAKDasMSwarnakarNKJainSEngineered PLGA nanoparticles: an emerging delivery tool in cancer therapeuticsCrit Rev Ther Drug Carrier Syst201128114521395514
   PubMed Web of Science ®Google Scholar
• ObadalovaIDammerOKrejcikLA solid form of apremilast and a process for preparing the samePatent NoWO2016169533A12016
   Google Scholar
• BudhianASiegelSJWineyKIHaloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug contentInt J Pharm2007336236737517207944
   PubMed Web of Science ®Google Scholar
• SoniADandagiPGadadAMastiholimathVSimvastatin-loaded PLGA nanoparticles for improved oral bioavailability and sustained release: effect of formulation variablesAsian J Pharm2011525764
   Google Scholar
• YeoYParkKControl of encapsulation efficiency and initial burst in polymeric microparticle systemsArch Pharm Res200427111214969330
   PubMed Web of Science ®Google Scholar
• AnzarNMirzaMAAnwerKPreparation, evaluation and pharmacokinetic studies of spray dried PLGA polymeric submicron particles of simvastatin for the effective treatment of breast cancerJ Mol Liq2018249609616
   Web of Science ®Google Scholar
• HonarySZahirFEffect of zeta potential on the properties of nanodrug delivery systems – a review (Part 1)Trop J Pharm Res201312255264
   Web of Science ®Google Scholar